vs
Omada Health, Inc.（OMDA）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
Omada Health, Inc.的季度营收约是Strata Critical Medical, Inc.的3.0倍（$68.0M vs $22.7M）。Omada Health, Inc.自由现金流更多（$9.6M vs $-10.2M）
Omada Health是美国头部数字化慢性病管理服务商，面向雇主、商业健康保险机构及医疗系统，提供针对2型糖尿病、高血压、肌肉骨骼疾病、心理健康等领域的个性化干预方案，搭配专业教练指导和数字化工具，助力用户改善长期健康水平。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
OMDA vs SRTA — 直观对比
营收规模更大
OMDA
是对方的3.0倍
$22.7M
自由现金流更多
OMDA
多$19.8M
$-10.2M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $68.0M | $22.7M |
| 净利润 | $-3.2M | — |
| 毛利率 | 66.3% | -0.9% |
| 营业利润率 | -3.7% | -18.4% |
| 净利率 | -4.7% | — |
| 营收同比 | — | 361.2% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.06 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OMDASRTA
| Q4 25 | — | $22.7M | ||
| Q3 25 | $68.0M | $49.3M | ||
| Q2 25 | $61.4M | $70.8M | ||
| Q1 25 | — | $54.3M | ||
| Q4 24 | — | $-8.7M | ||
| Q3 24 | — | $36.1M | ||
| Q2 24 | — | $67.9M | ||
| Q1 24 | — | $51.5M |
净利润OMDASRTA
| Q4 25 | — | — | ||
| Q3 25 | $-3.2M | $57.4M | ||
| Q2 25 | $-5.3M | $-3.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-11.3M | ||
| Q1 24 | — | $-4.2M |
毛利率OMDASRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | 66.3% | 23.6% | ||
| Q2 25 | 65.7% | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率OMDASRTA
| Q4 25 | — | -18.4% | ||
| Q3 25 | -3.7% | -11.4% | ||
| Q2 25 | -7.1% | -7.0% | ||
| Q1 25 | — | -14.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -19.7% | ||
| Q2 24 | — | -17.9% | ||
| Q1 24 | — | -19.2% |
净利率OMDASRTA
| Q4 25 | — | — | ||
| Q3 25 | -4.7% | 116.5% | ||
| Q2 25 | -8.7% | -5.3% | ||
| Q1 25 | — | -6.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -5.4% | ||
| Q2 24 | — | -16.7% | ||
| Q1 24 | — | -8.2% |
每股收益（稀释后）OMDASRTA
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.06 | $0.70 | ||
| Q2 25 | $-0.24 | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.6M | $31.0M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $217.3M | $279.1M |
| 总资产 | $287.5M | $325.5M |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资OMDASRTA
| Q4 25 | — | $31.0M | ||
| Q3 25 | $198.6M | $22.8M | ||
| Q2 25 | $223.1M | $58.8M | ||
| Q1 25 | — | $34.8M | ||
| Q4 24 | — | $18.4M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $26.3M | ||
| Q1 24 | — | $36.8M |
总债务OMDASRTA
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益OMDASRTA
| Q4 25 | — | $279.1M | ||
| Q3 25 | $217.3M | $283.0M | ||
| Q2 25 | $214.2M | $223.1M | ||
| Q1 25 | — | $219.7M | ||
| Q4 24 | — | $221.9M | ||
| Q3 24 | — | $233.5M | ||
| Q2 24 | — | $229.4M | ||
| Q1 24 | — | $236.6M |
总资产OMDASRTA
| Q4 25 | — | $325.5M | ||
| Q3 25 | $287.5M | $335.1M | ||
| Q2 25 | $303.0M | $257.9M | ||
| Q1 25 | — | $250.6M | ||
| Q4 24 | — | $256.7M | ||
| Q3 24 | — | $282.9M | ||
| Q2 24 | — | $280.3M | ||
| Q1 24 | — | $282.8M |
负债/权益比OMDASRTA
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.1M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $9.6M | $-10.2M |
| 自由现金流率自由现金流/营收 | 14.1% | -44.7% |
| 资本支出强度资本支出/营收 | 0.8% | 8.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-58.5M |
8季度趋势，按日历期对齐
经营现金流OMDASRTA
| Q4 25 | — | $-8.3M | ||
| Q3 25 | $10.1M | $-37.3M | ||
| Q2 25 | $-13.3M | $-3.1M | ||
| Q1 25 | — | $-246.0K | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $6.4M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | — | $-15.6M |
自由现金流OMDASRTA
| Q4 25 | — | $-10.2M | ||
| Q3 25 | $9.6M | $-40.1M | ||
| Q2 25 | $-13.8M | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
自由现金流率OMDASRTA
| Q4 25 | — | -44.7% | ||
| Q3 25 | 14.1% | -81.4% | ||
| Q2 25 | -22.6% | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
资本支出强度OMDASRTA
| Q4 25 | — | 8.1% | ||
| Q3 25 | 0.8% | 5.7% | ||
| Q2 25 | 1.0% | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -52.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 1.6% |
现金转化率OMDASRTA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OMDA
| Services | $62.9M | 93% |
| Hardware | $5.1M | 7% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
